$45M Drug Milestone Suit Against Shire Kept Alive In Del.

Law360 (May 11, 2018, 7:36 PM EDT) -- Irish pharmaceutical company Shire PLC lost a bid Friday to shut down a Delaware Chancery Court contract breach suit demanding an overdue $45 million drug development "milestone" payment, filed by the post-merger representatives of the drug's original owner.

In a ruling from the bench, Vice Chancellor J. Travis Laster refused to dismiss the case filed by Shareholder Representative Services LLC, which represents equity holders of FerroKin BioSciences Inc.

The vice chancellor said in part that it appeared that Shire "made up" regulator-approval deadlines that played a part in its defense of its refusal to pay the contracted amount.

"You in fact...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!